Clover Health Investments (CLOV) Stock Price, News & Analysis

Company Overview

Clover Health Investments, Corp. is a healthcare technology and Medicare Advantage company headquartered in Franklin, Tennessee. Through its insurance subsidiary, Clover Health Insurance Company, the company offers Medicare Advantage plans to eligible beneficiaries in select counties across the United States. Its plans are designed to provide coverage for hospital, medical and supplemental healthcare services through a managed-care structure.

Clover’s technology platform, Clover Assistant, is intended to support physicians by organizing patient information, identifying potential care needs and helping providers coordinate treatment. The platform is designed to give clinicians data-driven insights during patient visits while helping Clover manage care for its Medicare Advantage members.

Clover Health was founded in 2012 and became a publicly traded company in 2021 through a business combination with Social Capital Hedosophia Holdings Corp. III. The company has focused primarily on the Medicare Advantage market and has also participated in value-based care initiatives. Andrew Toy serves as chief executive officer, having previously held technology leadership roles at Clover.

Key Stats

• Today's Range: $4.58 to $4.69
• 50-Day Range: $4.10 to $5.10
• 52-Week Range: $1.58 to $5.59
• Volume: 3.35 million shs
• Average Volume: 4.33 million shs
• Market Capitalization: $2.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.75
• Consensus Rating: Hold

Clover Health Investments Stock Analysis - MarketRank™

Clover Health Investments scored higher than 47% of companies evaluated by MarketBeat, and ranked 541st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Hold

Consensus Rating

Clover Health Investments has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Clover Health Investments is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Clover Health Investments has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 183.33%

Earnings Growth

Earnings for Clover Health Investments are expected to grow by 183.33% in the coming year, from $0.06 to $0.17 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clover Health Investments is -91.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clover Health Investments is -91.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Clover Health Investments has a P/B Ratio of 7.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.77% of the float of Clover Health Investments has been sold short.

Short Interest Ratio / Days to Cover

Clover Health Investments has a short interest ratio ("days to cover") of 5.18.

Change versus previous month

Short interest in Clover Health Investments has recently decreased by 0.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clover Health Investments does not currently pay a dividend.

Dividend Growth

Clover Health Investments does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

Clover Health Investments has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Clover Health Investments this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for CLOV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Clover Health Investments to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Clover Health Investments insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,310,691.00 in company stock.

Percentage Held by Insiders

23.51% of the stock of Clover Health Investments is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.77% of the stock of Clover Health Investments is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Managed Healthcare
• Current Symbol: NASDAQ:CLOV
• CIK: 1801170
• Web: www.cloverhealth.com
• Phone: 201-432-2133
• Fax: N/A
• Employees: 724
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Clover Health Investments: $4.75
• High Price Target: $6.00
• Low Price Target: $2.50
• Potential Upside/Downside: +3.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 76.67
• P/E Growth: N/A
• Net Income: -$85.55 million
• Net Margins: -0.74%
• Pretax Margin: -0.74%
• Return on Equity: -4.20%
• Return on Assets: -2.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $1.92 billion
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 7.80

Miscellaneous

• Outstanding Shares: 531,160,000
• Free Float: 406,281,000
• Market Cap: $2.44 billion
• Optionable: Optionable
• Beta: 2.45